SAGE's (SAGE) zuranalone Risk/Benefit Not Very Favorable, Opportunity is Niche - Analyst

December 1, 2021 8:28 AM EST
Get Alerts SAGE Hot Sheet
Price: $37.75 -3.97%

Rating Summary:
    14 Buy, 12 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 18 | Down: 18 | New: 37
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Earlier today, Sage Therapeutics, Inc. (Nasdaq: SAGE), and Biogen Inc. (Nasdaq: BIIB) announced 12-month data for the cohort of patients (n=199), who received zuranolone 50 mg once nightly for 14-days as their initial dose in the ongoing Phase 3 open-label SHORELINE Study and had the opportunity to be followed for 12-months.

Of the 199 enrolled in the 50mg dose cohort, 149 (74.9%) responded (50% HAMD reduction from baseline), i.e. 50 (25%) did not respond. 3 withdrew from study.

Commenting on the announcement, Truist analyst Joon Lee, notes that the data came in “as largely expected.”

The analyst concludes: “Bottom line, 58% either did not respond or needing re-dosing, implying relapse. We don't think 50mg is a material improvement over 30mg and don't view risk/benefit is all that favorable. We think opportunity for zuranolone in MDD may be more niche.”

Truist maintains a "Hold" rating on the company's shares with $60 Price Target.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA, Trader Talk